Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway

Marta Codrich, Marina Comelli, Matilde Clarissa Malfatti, Catia Mio, Dilara Ayyildiz, Chi Zhang, Mark Kelley, Giovanni Terrosu, Carlo E.M. Pucillo, Gianluca Tell

Research output: Contribution to journalArticle

Abstract

The pathogenesis of colorectal cancer (CRC) involves different mechanisms, such as genomic and microsatellite instabilities. Recently, a contribution of the base excision repair (BER) pathway in CRC pathology has been emerged. In this context, the involvement of APE1 in the BER pathway and in the transcriptional regulation of genes implicated in tumor progression strongly correlates with chemoresistance in CRC and in more aggressive cancers. In addition, the APE1 interactome is emerging as an important player in tumor progression, as demonstrated by its interaction with Nucleophosmin (NPM1). For these reasons, APE1 is becoming a promising target in cancer therapy and a powerful prognostic and predictive factor in several cancer types. Thus, specific APE1 inhibitors have been developed targeting: i) the endonuclease activity; ii) the redox function and iii) the APE1-NPM1 interaction. Furthermore, mutated p53 is a common feature of advanced CRC. The relationship between APE1 inhibition and p53 is still completely unknown. Here, we demonstrated that the inhibition of the endonuclease activity of APE1 triggers p53-mediated effects on cell metabolism in HCT-116 colon cancer cell line. In particular, the inhibition of the endonuclease activity, but not of the redox function or of the interaction with NPM1, promotes p53 activation in parallel to sensitization of p53-expressing HCT-116 cell line to genotoxic treatment. Moreover, the endonuclease inhibitor affects mitochondrial activity in a p53-dependent manner. Finally, we demonstrated that 3D organoids derived from CRC patients are susceptible to APE1-endonuclease inhibition in a p53-status correlated manner, recapitulating data obtained with HCT-116 isogenic cell lines. These findings suggest the importance of further studies aimed at testing the possibility to target the endonuclease activity of APE1 in CRC.

Original languageEnglish (US)
Article number102675
JournalDNA Repair
Volume82
DOIs
StatePublished - Oct 1 2019

Fingerprint

Enzyme inhibition
Endonucleases
Metabolism
Colonic Neoplasms
Colorectal Neoplasms
Cells
HCT116 Cells
Neoplasms
Cell Line
DNA Repair
Oxidation-Reduction
Tumors
Repair
Organoids
Microsatellite Instability
Genomic Instability
Pathology
Microsatellite Repeats
Genes
Chemical activation

Keywords

  • APE1
  • APE1-inhibitors
  • BER
  • Colorectal cancer
  • Organoids
  • p53

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Codrich, M., Comelli, M., Malfatti, M. C., Mio, C., Ayyildiz, D., Zhang, C., ... Tell, G. (2019). Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway. DNA Repair, 82, [102675]. https://doi.org/10.1016/j.dnarep.2019.102675

Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway. / Codrich, Marta; Comelli, Marina; Malfatti, Matilde Clarissa; Mio, Catia; Ayyildiz, Dilara; Zhang, Chi; Kelley, Mark; Terrosu, Giovanni; Pucillo, Carlo E.M.; Tell, Gianluca.

In: DNA Repair, Vol. 82, 102675, 01.10.2019.

Research output: Contribution to journalArticle

Codrich, M, Comelli, M, Malfatti, MC, Mio, C, Ayyildiz, D, Zhang, C, Kelley, M, Terrosu, G, Pucillo, CEM & Tell, G 2019, 'Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway', DNA Repair, vol. 82, 102675. https://doi.org/10.1016/j.dnarep.2019.102675
Codrich, Marta ; Comelli, Marina ; Malfatti, Matilde Clarissa ; Mio, Catia ; Ayyildiz, Dilara ; Zhang, Chi ; Kelley, Mark ; Terrosu, Giovanni ; Pucillo, Carlo E.M. ; Tell, Gianluca. / Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway. In: DNA Repair. 2019 ; Vol. 82.
@article{e37c29bce300425d8b8a4cbb4d68d832,
title = "Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway",
abstract = "The pathogenesis of colorectal cancer (CRC) involves different mechanisms, such as genomic and microsatellite instabilities. Recently, a contribution of the base excision repair (BER) pathway in CRC pathology has been emerged. In this context, the involvement of APE1 in the BER pathway and in the transcriptional regulation of genes implicated in tumor progression strongly correlates with chemoresistance in CRC and in more aggressive cancers. In addition, the APE1 interactome is emerging as an important player in tumor progression, as demonstrated by its interaction with Nucleophosmin (NPM1). For these reasons, APE1 is becoming a promising target in cancer therapy and a powerful prognostic and predictive factor in several cancer types. Thus, specific APE1 inhibitors have been developed targeting: i) the endonuclease activity; ii) the redox function and iii) the APE1-NPM1 interaction. Furthermore, mutated p53 is a common feature of advanced CRC. The relationship between APE1 inhibition and p53 is still completely unknown. Here, we demonstrated that the inhibition of the endonuclease activity of APE1 triggers p53-mediated effects on cell metabolism in HCT-116 colon cancer cell line. In particular, the inhibition of the endonuclease activity, but not of the redox function or of the interaction with NPM1, promotes p53 activation in parallel to sensitization of p53-expressing HCT-116 cell line to genotoxic treatment. Moreover, the endonuclease inhibitor affects mitochondrial activity in a p53-dependent manner. Finally, we demonstrated that 3D organoids derived from CRC patients are susceptible to APE1-endonuclease inhibition in a p53-status correlated manner, recapitulating data obtained with HCT-116 isogenic cell lines. These findings suggest the importance of further studies aimed at testing the possibility to target the endonuclease activity of APE1 in CRC.",
keywords = "APE1, APE1-inhibitors, BER, Colorectal cancer, Organoids, p53",
author = "Marta Codrich and Marina Comelli and Malfatti, {Matilde Clarissa} and Catia Mio and Dilara Ayyildiz and Chi Zhang and Mark Kelley and Giovanni Terrosu and Pucillo, {Carlo E.M.} and Gianluca Tell",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.dnarep.2019.102675",
language = "English (US)",
volume = "82",
journal = "DNA Repair",
issn = "1568-7864",
publisher = "Elsevier",

}

TY - JOUR

T1 - Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway

AU - Codrich, Marta

AU - Comelli, Marina

AU - Malfatti, Matilde Clarissa

AU - Mio, Catia

AU - Ayyildiz, Dilara

AU - Zhang, Chi

AU - Kelley, Mark

AU - Terrosu, Giovanni

AU - Pucillo, Carlo E.M.

AU - Tell, Gianluca

PY - 2019/10/1

Y1 - 2019/10/1

N2 - The pathogenesis of colorectal cancer (CRC) involves different mechanisms, such as genomic and microsatellite instabilities. Recently, a contribution of the base excision repair (BER) pathway in CRC pathology has been emerged. In this context, the involvement of APE1 in the BER pathway and in the transcriptional regulation of genes implicated in tumor progression strongly correlates with chemoresistance in CRC and in more aggressive cancers. In addition, the APE1 interactome is emerging as an important player in tumor progression, as demonstrated by its interaction with Nucleophosmin (NPM1). For these reasons, APE1 is becoming a promising target in cancer therapy and a powerful prognostic and predictive factor in several cancer types. Thus, specific APE1 inhibitors have been developed targeting: i) the endonuclease activity; ii) the redox function and iii) the APE1-NPM1 interaction. Furthermore, mutated p53 is a common feature of advanced CRC. The relationship between APE1 inhibition and p53 is still completely unknown. Here, we demonstrated that the inhibition of the endonuclease activity of APE1 triggers p53-mediated effects on cell metabolism in HCT-116 colon cancer cell line. In particular, the inhibition of the endonuclease activity, but not of the redox function or of the interaction with NPM1, promotes p53 activation in parallel to sensitization of p53-expressing HCT-116 cell line to genotoxic treatment. Moreover, the endonuclease inhibitor affects mitochondrial activity in a p53-dependent manner. Finally, we demonstrated that 3D organoids derived from CRC patients are susceptible to APE1-endonuclease inhibition in a p53-status correlated manner, recapitulating data obtained with HCT-116 isogenic cell lines. These findings suggest the importance of further studies aimed at testing the possibility to target the endonuclease activity of APE1 in CRC.

AB - The pathogenesis of colorectal cancer (CRC) involves different mechanisms, such as genomic and microsatellite instabilities. Recently, a contribution of the base excision repair (BER) pathway in CRC pathology has been emerged. In this context, the involvement of APE1 in the BER pathway and in the transcriptional regulation of genes implicated in tumor progression strongly correlates with chemoresistance in CRC and in more aggressive cancers. In addition, the APE1 interactome is emerging as an important player in tumor progression, as demonstrated by its interaction with Nucleophosmin (NPM1). For these reasons, APE1 is becoming a promising target in cancer therapy and a powerful prognostic and predictive factor in several cancer types. Thus, specific APE1 inhibitors have been developed targeting: i) the endonuclease activity; ii) the redox function and iii) the APE1-NPM1 interaction. Furthermore, mutated p53 is a common feature of advanced CRC. The relationship between APE1 inhibition and p53 is still completely unknown. Here, we demonstrated that the inhibition of the endonuclease activity of APE1 triggers p53-mediated effects on cell metabolism in HCT-116 colon cancer cell line. In particular, the inhibition of the endonuclease activity, but not of the redox function or of the interaction with NPM1, promotes p53 activation in parallel to sensitization of p53-expressing HCT-116 cell line to genotoxic treatment. Moreover, the endonuclease inhibitor affects mitochondrial activity in a p53-dependent manner. Finally, we demonstrated that 3D organoids derived from CRC patients are susceptible to APE1-endonuclease inhibition in a p53-status correlated manner, recapitulating data obtained with HCT-116 isogenic cell lines. These findings suggest the importance of further studies aimed at testing the possibility to target the endonuclease activity of APE1 in CRC.

KW - APE1

KW - APE1-inhibitors

KW - BER

KW - Colorectal cancer

KW - Organoids

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=85071004071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071004071&partnerID=8YFLogxK

U2 - 10.1016/j.dnarep.2019.102675

DO - 10.1016/j.dnarep.2019.102675

M3 - Article

AN - SCOPUS:85071004071

VL - 82

JO - DNA Repair

JF - DNA Repair

SN - 1568-7864

M1 - 102675

ER -